Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Direct in Vitro Comparison of Daratumumab with Surrogate Analogs of CD38 Antibodies MOR03087, SAR650984 and Ab79

Jeroen Lammerts van Bueren, PhD, Danielle Jakobs, Niels Kaldenhoven, Marcel Roza, Sanne Hiddingh, Joyce Meesters, Marleen Voorhorst, Elke Gresnigt, Luus Wiegman, Antonio Ortiz Buijsse, Grietje Andringa, Marije B. Overdijk, PhD, Parul Doshi, PhD, Kate Sasser, Michel de Weers, PhD, Paul W.H.I. Parren, PhD

Blood (2014) 124 (21): 3474.

https://doi.org/10.1182/blood.V124.21.3474.3474

Published: 2014

Journal Articles

Towards CD38-Targeted Immunochemotherapy of Multiple Myeloma: Significant Improvement of Anti-Myeloma Effects of Lenalidomide, Bortezomib and Dexamethason by CD38-Specific Antibody Daratumumab, Even in Chemotherapy Resistant/Intolerant Patients

Inger S. Nijhof, MD, Jeroen Lammerts van Bueren, Berris van Kessel, Michel de Weers, Joost M Bakker, PhD, Paul W. H. I. Parren, PhD, Henk Lokhorst, MD, PhD, Tuna Mutis, MD PhD

Blood (2012) 120 (21): 4988.

https://doi.org/10.1182/blood.V120.21.4988.4988

Published: 2012

Journal Articles

Reconstructing the human hematopoietic niche in immunodeficient mice: opportunities for studying primary multiple myeloma

Blood (2012) 120 (3): e9–e16.

https://doi.org/10.1182/blood-2012-03-414920

Published: 2012

Includes: Supplemental data

Journal Articles

Reconstructing the Human Hematopoietic Niche: Opportunities for Studying Normal and Malignant Hematopoiesis,

Richard W Groen, PhD, Willy A Noort, PhD, Reinier Raymakers, MD, PhD, Henk-Jan Prins, Msc, Linda Aalders, Frans M Hofhuis, Berris van Kessel, Petra Moerer, Henk Rozemuller, PhD, Jan J. Schuringa, PhD, Joost de Bruijn, PhD, Michel de Weers, PhD, Paul W.H.I. Parren, PhD, Henk M. Lokhorst, MD, Tuna Mutis, MD PhD, Anton CM Martens, PhD

Blood (2011) 118 (21): 3412.

https://doi.org/10.1182/blood.V118.21.3412.3412

Published: 2011

Journal Articles

The Human CD38 Monoclonal Antibody Daratumumab Improves the Anti-Myeloma Effect of Lenalidomide with Dexamethasone in Vitro

Michel de Weers, PhD, Michael van der Veer, Berris van Kessel, Joost M Bakker, PhD, Shulamiet Wittebol, MD, Paul WHI Parren, PhD, Henk M. Lokhorst, MD, Tuna Mutis, MD PhD

Blood (2011) 118 (21): 5106.

https://doi.org/10.1182/blood.V118.21.5106.5106

Published: 2011

Journal Articles

Synergistic Action of the Human Inhibitory KIR Antibody IPH2102, and the Human CD38 Antibody Daratumumab to Enhance the Lysis of Primary Multiple Myeloma (MM) Cells in the Bone Marrow Mononuclear Cells (MNCs) From Myeloma Patients

Inger S. Nijhof, MD, Michel de Weers, PhD, Pascale Andre, PhD, Berris van Kessel, Henk M. Lokhorst, MD, Paul W.H.I. Parren, PhD, Yannis Morel, PhD, Tuna Mutis, MD PhD

Blood (2011) 118 (21): 1865.

https://doi.org/10.1182/blood.V118.21.1865.1865

Published: 2011

Journal Articles

Fusion Proteins of Ligands for NKG2D and CD20-Directed ScFvs Sensitize Lymphomas for NK Cell-Mediated Lysis

Christian Kellner, Daniela Hallack, Pia Glorius, Matthias Staudinger, Sahar Mohseni Nodehi, Tina Maurer, Roland Repp, Michel de Weers, Jan G.J. van De Winkel, Paul W.H.I. Parren, Andreas Humpe, Martin Gramatzki, Matthias Peipp

Blood (2010) 116 (21): 2843.

https://doi.org/10.1182/blood.V116.21.2843.2843

Published: 2010

Journal Articles

Daratumumab Directly Induces Human Multiple Myeloma Cell Death and Acts Synergistically with Conventional and Novel Anti-Myeloma Drugs

Sun-Young Kong, MD, PhD, Xian-Feng Li, Sabikun Nahar, Weihua Song, MD, Michel de Weers, Paul W.H.I. Parren, Paul Richardson, M.D., Ph.D., Nikhil C. Munshi, MD, Kenneth C. Anderson, Yu-Tzu Tai, PhD

Blood (2010) 116 (21): 3013.

https://doi.org/10.1182/blood.V116.21.3013.3013

Published: 2010

Journal Articles

In Vitro and In Vivo Efficacy of CD38 Directed Therapy with Daratumumab In the Treatment of Multiple Myeloma

Richard W Groen, Michael van der Veer, Frans M Hofhuis, Berris van Kessel, Michel de Weers, PhD, Paul W.H.I. Parren, PhD, Henk M Lokhorst, MD, PhD, Tuna Mutis, MD, PhD, Anton Martens, PhD

Blood (2010) 116 (21): 3058.

https://doi.org/10.1182/blood.V116.21.3058.3058

Published: 2010

Journal Articles

Towards Effective Immunotherapy of Multiple Myeloma: Enhanced Elimination of Myeloma Cells by Combination of Lenalidomide with the Human CD38 Monoclonal Antibody Daratumumab

Michael S. van der Veer, Michel de Weers, Berris van Kessel, Shulamiet Wittebol, Joost M Bakker, Paul W.H.I. Parren, Henk M Lokhorst, Tuna Mutis, MD, PhD

Blood (2010) 116 (21): 3059.

https://doi.org/10.1182/blood.V116.21.3059.3059

Published: 2010

Journal Articles

Improved Myeloma Targeting by Combination of the Human Anti-CD38 Antibody Daratumumab with Lenalidomide and Bortezomib

Michael S. van der Veer, Michel de Weers, Berris van Kessel, Joost M Bakker, Shulamiet Wittebol, Paul W.H.I. Parren, Henk M Lokhorst, Tuna Mutis, MD, PhD

Blood (2010) 116 (21): 3030.

https://doi.org/10.1182/blood.V116.21.3030.3030

Published: 2010

Journal Articles

A Unique New Humanized Mouse Model for Multiple Myeloma (MM): Opportunities for Studying MM In Its Natural Environment and for Preclinical Testing

Richard W Groen, Frans M Hofhuis, Linda Aalders, Berris van Kessel, Michel de Weers, PhD, Tuna Mutis, MD, PhD, Henk Lokhorst, MD, PhD, Anton C Martens, PhD

Blood (2010) 116 (21): 981.

https://doi.org/10.1182/blood.V116.21.981.981

Published: 2010

Journal Articles

The Humanized Multiple Myeloma Mouse Model: Opportunities for Studying the Pathogenesis of MM in Its Natural Environment.

Richard W.J. Groen, Frans M. Hofhuis, Henk-Jan Prins, Henk Rozemuller, PhD, Berris van Kessel, Michel de Weers, PhD, Henk Lokhorst, MD, PhD, Anton C.M. Martens, PhD

Blood (2009) 114 (22): 1847.

https://doi.org/10.1182/blood.V114.22.1847.1847

Published: 2009

Journal Articles

Daratumumab, a Novel Potent Human Anti-CD38 Monoclonal Antibody, Induces Significant Killing of Human Multiple Myeloma Cells: Therapeutic Implication.

Yu-Tzu Tai, Ph.D., Michel de Weers, Ph.D., Xian-Feng Li, MS, Weihua Song, MD, Sabikun Nahar, B.S., Joost M Bakker, Tom Vink, Daniëlle Jacobs, Lukas Oomen, Wim K Bleeker, Nikhil C. Munshi, MD, Jan G. J. van de Winkel, PhD, Paul W. H. I. Parren, PhD, Paul Richardson, M.D., Ph.D., Kenneth C. Anderson, MD

Blood (2009) 114 (22): 608.

https://doi.org/10.1182/blood.V114.22.608.608

Published: 2009

Journal Articles

Fully Human CD38 Antibodies Efficiently Trigger ADCC of Multiple Myeloma Cell Lines and Primary Tumor Cells.

Matthias Peipp, PhD, Michel de Weers, PhD, Thomas Beyer, PhD, Roland Repp, MD, Paul Parren, PhD, Thomas Valerius, MD, Jan G.J. van de Winkel, PhD

Blood (2005) 106 (11): 3377.

https://doi.org/10.1182/blood.V106.11.3377.3377

Published: 2005

NARROW

Direct in Vitro Comparison of Daratumumab with Surrogate Analogs of CD38 Antibodies MOR03087, SAR650984 and Ab79

Towards CD38-Targeted Immunochemotherapy of Multiple Myeloma: Significant Improvement of Anti-Myeloma Effects of Lenalidomide, Bortezomib and Dexamethason by CD38-Specific Antibody Daratumumab, Even in Chemotherapy Resistant/Intolerant Patients

Reconstructing the human hematopoietic niche in immunodeficient mice: opportunities for studying primary multiple myeloma

Reconstructing the Human Hematopoietic Niche: Opportunities for Studying Normal and Malignant Hematopoiesis,

The Human CD38 Monoclonal Antibody Daratumumab Improves the Anti-Myeloma Effect of Lenalidomide with Dexamethasone in Vitro

Synergistic Action of the Human Inhibitory KIR Antibody IPH2102, and the Human CD38 Antibody Daratumumab to Enhance the Lysis of Primary Multiple Myeloma (MM) Cells in the Bone Marrow Mononuclear Cells (MNCs) From Myeloma Patients

Fusion Proteins of Ligands for NKG2D and CD20-Directed ScFvs Sensitize Lymphomas for NK Cell-Mediated Lysis

Daratumumab Directly Induces Human Multiple Myeloma Cell Death and Acts Synergistically with Conventional and Novel Anti-Myeloma Drugs

In Vitro and In Vivo Efficacy of CD38 Directed Therapy with Daratumumab In the Treatment of Multiple Myeloma

Towards Effective Immunotherapy of Multiple Myeloma: Enhanced Elimination of Myeloma Cells by Combination of Lenalidomide with the Human CD38 Monoclonal Antibody Daratumumab

Improved Myeloma Targeting by Combination of the Human Anti-CD38 Antibody Daratumumab with Lenalidomide and Bortezomib

A Unique New Humanized Mouse Model for Multiple Myeloma (MM): Opportunities for Studying MM In Its Natural Environment and for Preclinical Testing

The Humanized Multiple Myeloma Mouse Model: Opportunities for Studying the Pathogenesis of MM in Its Natural Environment.

Daratumumab, a Novel Potent Human Anti-CD38 Monoclonal Antibody, Induces Significant Killing of Human Multiple Myeloma Cells: Therapeutic Implication.

Fully Human CD38 Antibodies Efficiently Trigger ADCC of Multiple Myeloma Cell Lines and Primary Tumor Cells.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only